ArticleVaccine2012
Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Evaluation of immune responses toFrontiers in veterinary science · 2022Pooled it
- Establishment of an I-ELISA method based on multi-epitope fusion protein for diagnosis of human brucellosis.PLoS neglected tropical diseases · 2025Article
- Unraveling brucellosis: advances in pathogenesis, diagnostic strategies, therapeutic innovations, and public health perspectives.Frontiers in medicine · 2025Review
- Development of a Plant-Expressed Subunit Vaccine against Brucellosis.Microorganisms · 2024Article
- Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study.AMB Express · 2024Article
- Oral vaccination with novel Lactococcus lactis mucosal live vector-secreting Brucella lumazine synthase (BLS) protein induces humoral and cellular immune protection against Brucella abortus.Archives of microbiology · 2023Article
- A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model.Infectious diseases of poverty · 2021Article
- Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice.Probiotics and antimicrobial proteins · 2021Article
- Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors ExpressingBioMed research international · 2020Article
- Immunization With a Combination of Four RecombinantFrontiers in veterinary science · 2020Article
- Article
- Immunogenicity of adenovirus and DNA vaccines co-expressing P39 and lumazine synthase proteins of Brucella abortus in BALB/c mice.Tropical animal health and production · 2018Article
- Characterization of novel Omp31 antigenic epitopes of Brucella melitensis by monoclonal antibodies.BMC microbiology · 2017Article
- Immunoreactivity evaluation of a new recombinant chimeric protein againstIranian journal of microbiology · 2016Article
- Brucella melitensis T cell epitope recognition in humans with brucellosis in Peru.Infection and immunity · 2014Article
- Review
- Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.Frontiers in cellular and infection microbiology · 2013Review
- A history of the development of Brucella vaccines.BioMed research international · 2013Review
- In silico design, cloning and high level expression of L7/L12-TOmp31 fusion protein of Brucella antigens.Research in pharmaceutical sciencesArticle
- Cloning and Expression ofAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Because of the serious economic and medical consequences of brucellosis, efforts are to prevent infection of domestic animals through vaccines. Many disadvantages are associated with the current Brucella melitensis Rev.1 vaccine prompting development of alternative vaccines and delivery. Escherichia coli (DH5α) was engineered to express a plasmid containing the inv gene from Yersinia pseudotuberculosis and the hly gene from Listeria monocytogenes. These recombinant invasive E. coli expressing B. melitensis outer membrane proteins (Omp31 or 16) or the periplasmic protein BP26 were evaluated for protection of mice against virulent B. melitensis. Importantly, these invasive E. coli vaccines induced significant protection against B. melitensis challenged mice. Invasive E. coli may be an ideal vaccine platform with natural adjuvant properties for application against B. melitensis since the E. coli delivery system is non-pathogenic and can deliver antigens to antigen-presenting cells promoting cellular immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.